dc.contributor.author | Hızal, Mutlu | |
dc.contributor.author | Bilgin, Burak | |
dc.contributor.author | Paksoy, Nail | |
dc.contributor.author | Açıkgöz, Özgür | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Gürbüz, Mustafa | |
dc.contributor.author | Ak, Naziye | |
dc.contributor.author | Yücel, Şebnem | |
dc.contributor.author | Ayhan, Murat | |
dc.contributor.author | Erol, Cihan | |
dc.contributor.author | Demirkıran, Aykut | |
dc.contributor.author | Mandel, Nil Molinas | |
dc.contributor.author | Shbair, Abdallah | |
dc.contributor.author | Gökmen, İvo | |
dc.contributor.author | Başoğlu, Tuğba | |
dc.contributor.author | Paydaş, Semra | |
dc.contributor.author | Demiray, Atike Gökçen | |
dc.contributor.author | İriağaç, Yakup | |
dc.contributor.author | Şakalar, Teoman | |
dc.contributor.author | Zeynelgil, Esra | |
dc.contributor.author | Tatlı, Ali Murat | |
dc.contributor.author | Bahçeci, Aykut | |
dc.contributor.author | Güven, Deniz Can | |
dc.contributor.author | Caner, Burcu | |
dc.contributor.author | Can, Alper | |
dc.contributor.author | Gülmez, Ahmet | |
dc.contributor.author | Karakaş, Yusuf | |
dc.contributor.author | Yalçın, Bülent | |
dc.contributor.author | Demirkazık, Ahmet | |
dc.contributor.author | Bilici, Ahmet | |
dc.contributor.author | Aydıner, Adnan | |
dc.contributor.author | Yumuk, Perran Fulden | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.date.accessioned | 2023-01-19T11:47:21Z | |
dc.date.available | 2023-01-19T11:47:21Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Hızal, M., Bilgin, B., Paksoy, N., Açıkgöz, Ö., Sezer, A., Gürbüz, M. ... Şendur, M. A. N. (2022). The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study. Journal of Cancer Research and Clinical Oncology, 148(6), 1501-1508. https://dx.doi.org/10.1007/s00432-021-03748-7 | en_US |
dc.identifier.issn | 0171-5216 | |
dc.identifier.issn | 1432-1335 | |
dc.identifier.uri | https://dx.doi.org/10.1007/s00432-021-03748-7 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/10337 | |
dc.description.abstract | Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In this multicenter study, we aimed to determine the real-life efficacy and safety of Osimertinib in pretreated advanced NSCLC patients with T790M mutation. Materials and methods This retrospective trial included advanced T790M-mutant pretreated NSCLC patients who received Osimertinib from 24 different centers in Turkey. Primary endpoint was time-to-treatment discontinuation (TTD). Secondary endpoints were objective response rate (ORR), overall survival (OS), and safety. Results Of 163 patients, 68.7% had EGFR exon 19 deletion and 22.7% had exon 21 L858R mutation. Osimertinib was given as second-line treatment in 96 patients (58.9%) and third-line in 48 patients (29.4%). After median of 13-month follow-up, median TTD was 21.6 months with an 82.2% ORR. Estimated median OS was 32.1 months. Grade 3-4 adverse events were seen in 11.7% of the patients. Conclusion Osimertinib is a highly effective option in second- or third-line treatment of NSCLC patients with T790M mutation, with a favorable safety profile. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Springer | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | EGFR | en_US |
dc.subject | Non-Small Cell Lung Cancer | en_US |
dc.subject | Osimertinib | en_US |
dc.subject | Second Line | en_US |
dc.subject | T790M | en_US |
dc.title | The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Journal of Cancer Research and Clinical Oncology | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0003-2715-4002 | en_US |
dc.authorid | 0000-0002-0443-6966 | en_US |
dc.identifier.volume | 148 | en_US |
dc.identifier.issue | 6 | en_US |
dc.identifier.startpage | 1501 | en_US |
dc.identifier.endpage | 1508 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1007/s00432-021-03748-7 | en_US |
dc.institutionauthor | Açıkgöz, Özgür | |
dc.institutionauthor | Bilici, Ahmet | |
dc.identifier.wosquality | Q2 | en_US |
dc.identifier.wos | 000679766900001 | en_US |
dc.identifier.scopus | 2-s2.0-85111543488 | en_US |
dc.identifier.pmid | 34331582 | en_US |
dc.identifier.scopusquality | Q1 | en_US |